GT
ACRS icon

Glenmede Trust’s Aclaris Therapeutics ACRS Stock Holding History

Glenmede Trust’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-74
Closed – – 2449
2020
Q2 		$0 Hold
74
– – ﹤0.01% 2430
2020
Q1 		$0 Hold
74
– – ﹤0.01% 2998
2019
Q4 		$0 Hold
74
– – ﹤0.01% 2999
2019
Q3 		$0 Sell
74
-1,782
-96% -$2.53K ﹤0.01% 2998
2019
Q2 		$4 Sell
1,856
-342
-16% -$1.86K ﹤0.01% 2674
2019
Q1 		$13 Hold
2,198
– – ﹤0.01% 2253
2018
Q4 		$16 Buy
+2,198
New +$22.7K ﹤0.01% 2074

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust's ACRS Position: Q3 2020 in Review

Glenmede Trust sold out of Aclaris Therapeutics (ACRS) in Q3 2020, closing a stake of 74 shares.

Glenmede Trust first reported a position in ACRS in Q4 2018 and held it in 7 quarters. The position peaked at $16 in Q4 2018. 57 funds tracked by Wall St. Rank hold ACRS as of Q3 2020.

  • Glenmede Trust reported no remaining Aclaris Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Glenmede Trust sold 74 Aclaris Therapeutics shares in Q3 2020.
  • Glenmede Trust first reported a position in Aclaris Therapeutics in Q4 2018 and held it in 7 quarters.
  • Glenmede Trust's Aclaris Therapeutics position peaked at $16 in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2020.

Based on Glenmede Trust's 13F filing for Q3 2020, filed 16 Nov 2020.